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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• The incidence of both type 1 and type 2 diabetes is rising
among children and adolescents.
• Data on the prevalence of type 1 and type 2 diabetes are
limited.
• Routine clinical databases can be used to study the
prevalence and epidemiology of treatment, depending on
the completeness of data capture and their
representativeness of the whole population.
WHAT THIS STUDY ADDS
• The prevalence of insulin prescribing appears to vary
among countries, being highest in Sweden (3.5 per 1000
population) and lowest in Italy (1.1 per 1000 population).
• The prevalence of oral anti-diabetic prescribing ranges from
0.08 per 1000 population in Sweden and Germany to 0.21
per 1000 population in the UK; however, the total number
of patients receiving oral anti-diabetics is low.
• It is possible to use the same study protocol across clinical
databases in Europe to study the prevalence of type 1
diabetes in children.
• Routine clinical databases can identify the prevalence of
type 1 diabetes prescribing and could be used to study the
secular changes in disease prevalence in children.
AIMS
The aim of this study was to compare the prevalence of diabetes in children across
seven European countries, when using prescribing of anti-diabetics as a proxy for
diabetes. A secondary aim was to assess the potential for collaboration between
countries using different databases in diabetes research.
METHODS
Data were obtained from population-based clinical databases in seven European
countries. The study population comprised children aged 0–18 years. Prescriptions
were categorized using the Anatomic Therapeutic Chemical (ATC) classification. The
one-year user prevalence in 2008 was calculated for each country and stratified by
age and sex.
RESULTS
We studied a total of 5.8 million children and adolescents. The prevalence of insulin
prescribing varied between 1.1 and 3.5 per 1000 population, being highest in Sweden
and lowest in Italy. In all countries, novel insulin analogues were the most commonly
used insulins. The prevalence of oral anti-diabetic prescribing ranged from 0.08 per
1000 individuals in Sweden and Germany to 0.21 per 1000 population in the UK.
Overall, the absolute number of oral anti-diabetic users was very low.
CONCLUSION
This study shows that there is a varying frequency of type 1 diabetes in children and
adolescents across Europe. We also demonstrated that it is possible to obtain similar
information from different clinical databases within Europe, which would allow
continuous monitoring of type 1 diabetes. Owing to the lack of indications in most of
the databases, this approach is less suitable for type 2 diabetes.
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Introduction
The number of people with diabetes is increasing due to
several reasons [1], so the treatment and management of
diabetes poses a major burden for healthcare systems
worldwide [2]. The incidence of both type 1 and type 2
diabetes is also rising among children and adolescents
[3, 4].
A recent analysis of 20 population-based diabetes reg-
isters in 17 European countries showed a yearly increase in
the incidence of type 1 childhood diabetes, ranging from
0.6 to 9.3%, in all but two countries. The overall annual
increase (age 0–14 years) was 3.9% [95% confidence inter-
val (CI) 3.6–4.2].The predicted annual number of new cases
for 2020 is 24 400, with a doubling of numbers in children
younger than 5 years and a more even distribution across
age groups than at present [5].
However, data on the prevalence of type 1 and 2 dia-
betes in children and adolescents are limited.This informa-
tion is particularly important from a health policy point of
view because it will enable the monitoring of disease
burden, which is directly related to the planning of health-
care resources.
Routine clinical databases are powerful instruments to
study the prevalence and epidemiology of treatments.The
data collection process is embedded into routine clinical
practice, no additional ad hoc database has to be main-
tained and no additional human resources are required to
keep records up to date [6].
Hsia et al. have previously studied the prevalence of
type 1 and type 2 diabetes in children and adolescents in
the UK using prescribing data in a routine clinical data-
base [7]. The authors showed that the prevalence of chil-
dren receiving insulin and oral anti-diabetic drugs for
diabetes has increased two- and eightfold, respectively,
between 1998 and 2005. The study by Hsia et al. demon-
strated the potential of using existing routine clinical
databases in studying the prevalence of diabetes. Overall,
there is a considerable potential in using these routine
databases in diabetes epidemiological studies across
Europe.
The present study applied the same methodology used
by Hsia et al. [7] to investigate the prescribing of anti-
diabetics and thereby the prevalence of diabetes in chil-
dren across seven European countries. It also serves as a
proof-of-concept study to demonstrate the potential for
collaboration between countries using different databases
in diabetes research.
The aim of this study was to compare the one-year
prevalence in 2008 of anti-diabetic drug prescribing
(insulin and oral anti-diabetics) in children and adolescents
aged 0–18 years using population-based clinical databases
from seven European countries. Also, we wanted to inves-
tigate the potential of obtaining similar information from




We conducted a prevalence study using the following
databases: IADB.nl database (The Netherlands), Gmuender
ErsatzKasse (GEK; Germany), IMS Disease Analyser (UK),
Norwegian Prescription Database (NorPD), National Pre-
scription Register (Finland), the Lombardy region prescrip-
tion database (Italy), prescription databases of Central
and North Denmark regions and the Swedish Prescribed
Drug Register (PDR, Sweden). All databases except the
IMS Disease Analyser are population-based prescription
databases. The IMS Disease Analyser is a patient record
database.
A common study protocol was developed, considering
the information available in each database. A standardized
data specification was sent to each participating centre.
Medications were classified according to the Anatomical
Therapeutic Chemical (ATC) classification system [8].
From each database, the requested information com-
prised patient demographics and the number of patients
receiving insulin and oral anti-diabetic drug prescriptions
by ATC subtherapeutic level, sex and age group.
The following details describe each database at the
time of study commencement.
UK: IMS Disease Analyser The data from the UK were
derived from the IMS Disease Analyser (IMS DA) [7, 9]. This
database contains approximately 3 million anonymous
patient records from about 570 general practitioners (GPs),
representing about 5% of the UK population [6, 10]. Infor-
mation held on the IMS DA includes patient demograph-
ics, indications for treatment and details of prescriptions
issued in primary care.
The Netherlands The IADB.nl database is a pharmacy pre-
scription database from community pharmacies located in
The Netherlands (http://www.iadb.nl).
Dutch patients usually register at a single pharmacy,
and therefore an almost complete overview of drug
history, excluding over-the-counter medications and
in-hospital prescriptions, can be achieved. The database
records longitudinal drug prescriptions records from more
than 50 community pharmacies in The Netherlands, cover-
ing a population of 500 000 people since 1999. The
number of children aged 0–18 years in this population was
approximately 123 000 in 2008 [11, 12].
Germany Data from Germany were derived from
individual-level prescription data from the Gmuender
ErsatzKasse (GEK), one of about 270 different statutory
health insurance companies in Germany. More than 85%
(70.2 million) of all German inhabitants (82 million) are
enrolled in a statutory health insurance company. The GEK
comprises 1.75 million members located in all regions of
Germany.The data from the GEK are especially representa-
A. Neubert et al.
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tive for children and youths [13, 14]. The data file for this
analysis comprised 341 544 enrollees aged 0–18 years in
2008.
Sweden Swedish data were derived from the Swedish Pre-
scribed Drug Register (PDR, Sweden), which was estab-
lished in 2005. The register contains data with unique
patient identifiers for all dispensed prescriptions for the
whole population of Sweden (9 million inhabitants).
Patient-specific information, such as age, sex and place
of living, is included in the register, which also contains
information concerning dispensed substance, brand
name, formulation, package size, amount, expenditure,
reimbursement and prescriber’s profession and practice.
The register is complete for the entire population of the
country (patient identity data are missing for <0.3% of all
items) [15].
Norway Norwegian data were retrieved from the Norwe-
gian Prescription Database (NorPD) managed by the Nor-
wegian Institute of Public Health (NIPH). The NorPD is a
prescription database established in 2004, covering the
entire nation of Norway (4.8 million inhabitants).The popu-
lation aged 0–18 years covered was 1 133 758 in 2008.
The database contains information from all drugs pre-
scribed (reimbursed or not) and dispensed at pharmacies
to individual patients living outside institutions, i.e. ambu-
lant care. All pharmacies in Norway (~650) are obliged by
law to report their data electronically every month to NIPH.
Data include patient demographic data, drug information
and details of the dispensing pharmacy and the prescriber.
To date there are over 4.6 million individuals and more
than 208 million prescriptions in the database [16].
Denmark Danish data came from the regions of Central
and North Denmark, with a combined population of 1.8
million people (approximately 30% of the entire Danish
population). These regions are served by pharmacies
equipped with electronic accounting systems used prima-
rily to secure reimbursement from the Danish National
Health Service, which refunds part of the cost of most pre-
scribed medicines, including anti-diabetics. Prescription
information, including the customer’s civil registration
number, the type and amount of drug prescribed and the
date the drug was dispensed, is transferred from the phar-
macies to a regional prescription database at Aarhus Uni-
versity. We used this database to identify all prescriptions
for insulin or oral anti-diabetics for all patients aged 0–18
years.
A more detailed description of the prescription data-
bases in the Nordic (Scandinavian) countries is published
elsewhere [17]. All drugs in the Nordic Countries are clas-
sified according to the ATC classification system [8].
Italy The data from Italy were retrieved from the Lom-
bardy region prescription database, which stores all com-
munity (i.e. outside hospitals) prescriptions, reimbursed by
the National Health Service (NHS) and issued to individuals
living in the Lombardy region, in northern Italy. Informa-
tion held on the Lombardy region prescription database
includes patient demographics and prescription details.
Data were managed and analysed using an anonymous
patient code. The study population was composed of
1 702 851 children and adolescents aged 0–18 years, male/
female ratio 1.06, living in the Lombardy region. The study
sample represented 15% of the Italian paediatric popula-
tion [18–20].
Study population
The study population comprised all individuals aged 0–18
years who had received at least one prescription for insulin
or an oral anti-diabetic drug between 1 January 2008 and
31 December 2008.
Anti-diabetic drugs were classified based on the WHO
ATC [8] therapeutic level A10 (drugs used in diabetes) and
stratified according to the subsequent levels as follows:
A10A (insulins and analogues); and A10B (blood-glucose-
lowering drugs, excluding insulins). In addition, the propor-
tion of insulin analogues within the different insulin
groups was examined. Table 1 shows the ATC codes used
for individual drug classes. The age classification of the
Table 1
Anti-diabetic drugs by Anatomical Therapeutic Chemical (ATC) code and
drug class
ATC code Drug name
Insulin
A10AB Insulins and analogues for injection, fast acting
A10AB01–A10AB03 Insulin (human/beef/pork)
A10AB04–A10AB06 Insulin analogues (lispro/aspart/glulisine)
A10AC Insulins and analogues for injection, intermediate
acting
A10AC01–A10AC03 Insulin human/beef/pork
A10AC04 Insulin analogue (lispro)
A10AD Insulins and analogues for injection, intermediate
acting combined with fast acting
A10AD01–A10AD03 Insulin (human/beef/pork)
A10AD04–A10AD05 Insulin analogues (lispro/aspart)





A10BB Sulfonamides, urea derivatives
A10BC Sulfonamides (heterocyclic)




A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BX Other blood-glucose-lowering drugs, excluding
insulins
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International Conference of Harmonization was modified
in this study, and the age bands were stratified as follows:
0–1, 2–5, 6–11 and 12–18 years.
Data analysis
Prevalence was defined as the number of individuals with
at least one prescription of anti-diabetic drugs divided by
the total number of individuals aged 0–18 years within the
study period. In the Scandinavian and Dutch prescription
databases, prevalence was defined as the number of indi-
viduals with at least one prescription of anti-diabetic drugs
divided by the total number of inhabitants aged 0–18
years as provided by the national statistics institutes. In the
Italian database, the total number of individuals equalled
the number of inhabitants in the Lombardi region of Italy.
In the databases from Germany and the UK, the denomi-
nator was the total number of patients aged 0–18 years in
the database. Data were stratified by age groups and
country using the Poisson distribution with a 95% confi-
dence interval. Statistical analyses were conducted using
STATA/SE version 11.0 (Stata Corp., College Station, TX,
USA).
Results
The total population comprised 5 893 657 children and
adolescents aged 0–18 years in seven databases in 2008.
Table 2 shows the distribution of anti-diabetic drug use in
children and adolescents by anti-diabetic drug type, sex
and country.
Insulin prescribing
The overall prevalence of insulin prescribing varied
between 1.1 per 1000 population (95% CI 1.1–1.2) and 3.5
per 1000 population (95% CI 3.4–3.6). In 2008 the preva-
lence of insulin prescribing in children and adolescents
aged 0–18 years was highest in Sweden (3.5 per 1000
population), followed by Norway (2.6 per 1000 population)
and Denmark (2.2 per 1000 population), and was lowest in
Italy (1.1 per 1000 population; Figure 1). The prevalence of
insulin prescribing in Sweden was about three times that
in Italy. The prescribing of insulin was slightly higher in
boys than in girls in five countries (The Netherlands,
Norway, UK, Italy and Sweden), but not in Denmark and
Germany.
In all countries apart from the UK, between 95 and
100% of patients received fast-acting insulin. In the UK,
80% of boys and 89% of girls received fast-acting insulin,
respectively. Long-acting insulins were received by more
than 50% of patients in all countries except Germany and
Norway, where only 42 and 35% of boys and 47 and 36% of
girls received long-acting insulins, respectively.
More than 90% of fast-acting insulin prescriptions were
analogues in all countries except in Germany (75% in boys
and 80% in girls) and in Denmark (56% in girls and boys).
One hundred per cent of long-acting insulin prescriptions
were analogues in all countries except Denmark, 45.4% in
boys and 41.9% in girls, respectively (Table 2).
With respect to intermediate-acting insulins, fixed com-
binations with fast-acting insulin (A10AD) were prescribed
more commonly in Italy, Denmark and the UK, whereas in
Norway more single intermediate-acting insulins were pre-
scribed (Table 2).
Oral anti-diabetics
The prevalence of oral anti-diabetic prescribing ranged
from 0.08 per 1000 population in Sweden (95% CI 0.06–
0.09) and Germany (95% CI 0.04–0.10) to 0.21 per 1000
population (95% CI 0.15–0.27) in the UK (Figure 2). Bigu-
anides (A10BA) were favoured over other oral anti-diabetic
drug types; metformin was the most commonly prescribed
oral anti-diabetic drug in all countries (Table 2). The preva-
lence of oral anti-diabetic prescribing was higher in girls in
all seven countries, in particular the UK (0.36 per 1000
population) and Italy (0.24 per 1000 population; Figure 2).
With respect to age, the prevalence of oral anti-diabetic
prescribing was highest in those aged 12–18 years in six
countries (Sweden, Norway, Denmark, UK, Italy and
Germany), with the UK being the country with the highest
prevalence (0.47 per 1000 population).
In The Netherlands, the prescribing of oral anti-
diabetics was highest in those aged 6–11 years. The use of
oral anti-diabetics in children aged less than 6 years was
extremely low in all countries except Italy (Figure 3).
Discussion
In this study, among 5.8 million children and adolescents in
seven different European countries, we found that there is
a variation in the prescribing of anti-diabetic drugs among
countries, indicating differences in the prevalence of type 1
diabetes and variations in the use of oral anti-diabetics.
We were unable to identify data on prevalence from
the literature to compare our results. However, the
EURODIAB registers previously reported substantial varia-
tions in incidence (new cases) of childhood type 1 diabetes
among countries ranging from 10.3 to 52.6 per 100 000
persons [5].
One limitation of this study is the variation in the
denominators used for the different databases. While the
Scandinavian databases (Denmark, Sweden and Norway)
used prescriptions issued to the entire population and
the number of inhabitants as provided by their national
institutes of statistics, the prescription databases from
Germany and Italy used the number of individuals cap-
tured in their database. Likewise, the clinical patient data-
base from the UK used all individuals registered with the
GPs contributing to the database. This means the latter
databases only looked at subpopulations, whereas the
Scandinavian databases looked at their entire population,
A. Neubert et al.
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which may have caused a slight shift of the data from the
non-Scandinavian databases.
For the IMS DA, a very good correlation between the
database population and the UK population in terms of
age and male-to-female ratio has been reported.The panel
of GPs is broadly representative of the UK population,
although there is under-representation of smaller prac-
tices and of practices in Scotland and Northern Ireland, and
there is a slight over-representation of younger doctors
[10]. The health insurance data from Germany have been
found to be particularly representative for children and
youths [14].
Differences in the source of data among databases may
also have an impact on the comparability of the data.
A limitation of data from health insurance claim data-
bases (e.g. from Germany and Italy) is that only prescrip-
tions reimbursed by the national health systems are
included. Private prescriptions and over-the-counter drugs
are not included. Nevertheless, the proportion of privately
insured patients in Germany, for instance, is only 9%. The
same applies for Italy. With respect to prescribing status,
insulin and oral antidiabetics are ‘prescription only medi-
cine’ in all countries. Therefore, the exclusion of over-the-

































Prevalence of insulin prescribing in children and adolescents aged 0–18 years with 95% confidence interval from seven European countries. Overall ( );





























Prevalence of oral anti-diabetic drug prescribing in children and adolescents aged 0–18 years by sex and country with 95% confidence interval from seven
European countries. Overall ( ); boys ( ); girls ( )
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Nevertheless, all databases have previously been used
in research and represented data from their country of
origin [6, 7, 11–13, 18, 20].
Our study showed the highest prevalence of insulin
prescribing in Sweden (3.52 per 1000 individuals), followed
by Norway (2.6 per 1000 population), Denmark (2.2 per
1000 population) and the UK (2.1 per 1000 population).
Prevalences in the latter two countries were similar,
whereas in Germany (1.9 per 1000 population) it was
somewhat lower and in Italy it was lowest (1.1 per 1000
population).
The pattern of these findings is similar to the results
reported by Patterson et al. [5]. Although Patterson et al.
reported on the incidence, highest numbers were seen in
Sweden, followed by Norway, Denmark, UK and Germany.
Furthermore, the data reported by Patterson et al. indi-
cated a north–south gradient, i.e. incidences were highest
in the northern coutnries and lower in southern countries.
This is in line with our data, where highest rates were found
in Scandinavia and lowest in Italy.
Another explanation for these between-country differ-
ences is a relationship between genetic disposition
and environmental factors and the occurrence of type 1
diabetes [21].
Incidence rates for type 1 diabetes in Italy vary between
6.1 and 34.0 per 100 000 per year, which has been attrib-
uted to the genetic heterogeneity in the Mediterranean
area [21, 22]. The Sardinia region has one of the highest
incidence rates of type 1 diabetes in the world, with inci-
dence rates about threefold higher than in the Liguria
region, which has the second highest overall incidence in
Italy [22]. However, we used data from one of the regions
with the lowest incidence of type 1 diabetes [22, 23]. This
may explain why Italy presents with the lowest prevalence
of anti-diabetic prescribing in our study population.
In addition, different prescribing practices and different
diagnostic criteria before treatment initiation may cause
variations in anti-diabetes drug prescribing between coun-
tries. However, with respect to treatment of type 1 diabe-
tes, the impact of these factors is rather small because the
only treatment option for type 1 diabetes is substitution
therapy with insulin. There may be different criteria when
treatment is initiated, but this is mainly a question of time
because these patients always will need insulin at some
point.
To our knowledge, this is the first study to investigate
anti-diabetic drug use in the paediatric population in
seven different countries across Europe. We have shown
that there is a high use of insulin analogues in the paedi-
atric population. Analogues are relatively new to the
market and have been deemed to be particularly suitable
for the paediatric and adolescent population. Our data
show that this seems to have been put into practice.
However, analogues have also been heavily marketed,
which may have influenced prescribing practices [24].
This study has further demonstrated the potential to
use information from several European clinical databases
for paediatric research, as proposed by Neubert et al. [6].
We have shown that routine clinical databases can be used
to monitor the prevalence of diabetes. Despite the differ-
ences in prevalences which we observed and in line with
previously published data, at least in children insulin pre-
scribing is a good surrogate for type 1 diabetes [7]. The
results of the present study clearly demonstrate that it
would be feasible to utilize these databases as an auto-
mated system to study the prevalence of type 1 diabetes in
children.
This is not so much the case with respect to the use of
oral anti-diabetic drugs. The number of patients receiving






























Prevalence of oral anti-diabetic drug prescribing by age groups and country with 95% confidence interval in seven European countries. Aged 0–1 ( ); aged
2–5 ( ); aged 6–11 ( ); aged 12–18 ( )
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(0.012%). The UK stood out with the highest prevalence of
oral anti-diabetics (0.36 per 1000), followed by Italy (0.24
per 1000). The most frequently prescribed oral anti-
diabetic in all countries was metformin. Metformin is cur-
rently licensed in most countries for the treatment of type
2 diabetes in children above 10 years of age; however, it is
also increasingly used off label for the treatment of poly-
cystic ovarian syndrome and obesity [25, 26]. Hsia et al.
were able to estimate the prevalence of type 2 diabetes in
children based on the indication for the prescriptions and
found a high proportion of oral anti-diabetics used for
PCOS [7]. However, in our present study, not all databases
record the indications for the prescription; hence, we were
unable to estimate the prevalence of children receiving
oral anti-diabetics for the treatment of type 2 diabetes.
Consequently, some of our routine prescribing databases
are less suitable for the assessment of type 2 diabetes.
Conclusion and future research
Our study confirms previous findings on varying frequency
of type 1 diabetes in children and adolescents using pre-
scribed insulin as a proxy for type 1 diabetes.
We demonstrated that it is possible to use the same
study protocol across clinical databases in seven different
EU countries to study type 1 diabetes in children. Owing to
a lack of indications in some of the databases and as oral
anti-diabetics can be used off label for other indications,
using them to study prevalence of type 2 diabetes is less
appropriate because they are not such a good proxy as
insulin is for type 1 diabetes.
As the next step, an automated long-term tracking
system to monitor the prevalence of type 1 diabetes in
children could be developed; however, further research is
still needed for healthcare systems to benefit from this.
Surely, another step would be to refine the techniques in
order to identify annual incidence as well as prevalence.
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